Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor

#2949

Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.

Aim(s): We present a case of hypercalcemia due to a metastatic pancreatic NET treated with sunitinib.

Materials and methods: A 65-year-old man was found to have multiple tumors in the liver, spleen and pancreas accidentally in 2011. Considering the tumors unresectable he decided to adopt Chinese herbs treatment, and he has had stable disease until 2014. On June 2014, the patient suddenly developed hypercalcemia(5.2mmol/L) with dizziness, nausea and vomiting. Abdominal contrast-enhanced CT scan showed the lesions were larger than before. The histology of the spleen lesion showed a well-differentiated NET (Ki-67 5%). His calcium level gradually decreased to normal after treated with octreotide LAR. However a few months later the patient developed hypercalcemia (3.71mmol/L) again. Further examination revealed no signs of parathyroid diseases or bone metastases. Then the patient was prescribed sunitinib 37.5mg per day.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wang C

Authors: Wang C, Qi Z, Tan H, Tan H,

Keywords: hypercalcemia, pancreatic NET, sunitinib,